股本结构
单位：万股
| 公告日期 | 2024-03-28 | 2024-03-28 | 2023-11-13 | 2023-11-13 | 2023-08-14 | 2023-08-14 |
|---|---|---|---|---|---|---|
| 证券总股本 | 1017.38 | 1017.40 | 1017.38 | 1017.40 | 1017.38 | 1017.40 |
| 普通股本 | 1017.38 | 1017.40 | 1017.38 | 1017.40 | 1017.38 | 1017.40 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-03-28 | 2023-12-31 | 2023-11-13 | 2023-09-30 | 2023-08-14 | 2023-06-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-03-28 | 1017.38 | 未披露 | 定期报告 | 2024-03-28 |
| 2024-03-28 | 1017.40 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Sale of common stock to related entities, net of transaction costs
|
2023-12-31 |
| 2023-11-13 | 1017.38 | 未披露 | 定期报告 | 2023-11-13 |
| 2023-11-13 | 1017.40 | 未披露 | 定期报告 | 2023-09-30 |
| 2023-08-14 | 1017.38 | 未披露 | 定期报告 | 2023-08-14 |
| 2023-08-14 | 1017.40 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Sale of common stock, net of transaction costs
|
2023-06-30 |
| 2023-04-28 | 1017.38 | 未披露 | 定期报告 | 2023-04-25 |
| 2023-03-29 | 814.33 | 未披露 | 定期报告 | 2023-03-21 |
| 2022-11-14 | 814.30 | 未披露 | 定期报告 | 2022-11-14 |
| 2022-10-03 | 812.24 | 未披露 |
更多>>
On September 27, 2022, Cocystal Pharma, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Incorporation (the “Amendment”) with the Delaware Secretary of State to effect a reverse stock split of all outstanding shares of the Company’s common stock at a ratio of one-for-12.
|
2022-10-11 |
| 2022-05-11 | 9746.90 | 未披露 | 定期报告 | 2022-05-11 |
| 2022-04-11 | 9746.88 | 未披露 | 定期报告 | 2022-04-11 |
| 2022-03-23 | 9746.90 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Sale of common stock, net of transaction costs
|
2021-12-31 |
| 2021-08-16 | 9746.88 | 未披露 | 定期报告 | 2021-08-12 |
| 2021-08-16 | 9746.90 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Sale of common stock, net of transaction costs
|
2021-06-30 |
| 2021-05-07 | 9746.88 | 未披露 |
更多>>
1.Common stock offered 26,000,000 shares.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 71,468,755 shares of common stock outstanding as of May 3, 2021.
|
2021-05-07 |
| 2021-05-17 | 7146.90 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Sale of common stock, net of transaction costs
|
2021-03-31 |
| 2021-03-17 | 7146.88 | 未披露 | 定期报告 | 2021-03-15 |
| 2021-05-05 | 7043.88 | 未披露 |
更多>>
from December 31, 2019 to December 31, 2020
Sale of common stock, net of transaction costs
|
2020-12-31 |
| 2020-11-13 | 6856.35 | 未披露 | 定期报告 | 2020-11-13 |
| 2020-11-13 | 6856.40 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Sale of common stock, net of transaction costs
|
2020-09-30 |
| 2020-08-31 | 6642.64 | 未披露 |
更多>>
1.Common stock offered 14,285,715 shares of common stock.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 52,140,699 shares of common stock outstanding as of August 25, 2020.
|
2020-08-31 |
| 2020-05-13 | 5214.07 | 未披露 |
更多>>
From December 31, 2019 to March 10, 2020
Sale of common stock, net of transaction costs
1.Common stock offered 5,037,038 shares of common stock
2.The number of shares common stock to be outstanding immediately after this offering is based on 47,103,661 shares of common stock outstanding as of March 9, 2020 and excludes
|
2020-03-10 |
| 2020-02-28 | 4710.37 | 未披露 |
更多>>
1.Common stock offered 8,461,540 shares of common stock
2.The number of shares common stock to be outstanding immediately after this offering is based on 38,642,121 shares of common stock outstanding as of February 26, 2020
|
2020-02-28 |
| 2020-01-31 | 3864.21 | 未披露 | 定期报告 | 2020-01-31 |
| 2020-03-27 | 3515.00 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Sale of common stock, net of transaction costs
|
2019-12-31 |
| 2019-11-04 | 3515.01 | 未披露 | 定期报告 | 2019-11-04 |
| 2019-05-10 | 3162.06 | 未披露 |
更多>>
from December 31, 2018 to March 29, 2019
Sale of common stock, net of transaction costs
|
2019-03-29 |
| 2019-04-01 | 2993.80 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Exercise of common stock options
Sale of common stock, net of transaction costs
Convertible debt instruments
|
2018-12-31 |
| 2018-08-09 | 2992.31 | 未披露 |
更多>>
from December 31, 2017 to June 8, 2018
Exercise of common stock options
Sale of common shares and issuance of warrants
Convertible debt instruments
|
2018-06-08 |
| 2018-04-30 | 2440.24 | 未披露 | 定期报告 | 2018-04-25 |
| 2018-05-10 | 2440.24 | 未披露 |
更多>>
from December 31, 2017 to March 31, 2018
Exercise of common stock options
|
2018-03-31 |
| 2018-03-12 | 2427.47 | 未披露 | 定期报告 | 2018-03-12 |
| 2018-03-21 | 2427.45 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Exercise of common stock options
Sale of common stock
|
2017-12-31 |
| 2017-03-31 | 71.40 | 未披露 | 定期报告 | 2016-12-31 |
From December 31, 2022 to December 31, 2023
Sale of common stock to related entities, net of transaction costs
From March 31, 2023 to June 30, 2023
Sale of common stock, net of transaction costs
On September 27, 2022, Cocystal Pharma, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Incorporation (the “Amendment”) with the Delaware Secretary of State to effect a reverse stock split of all outstanding shares of the Company’s common stock at a ratio of one-for-12.
From December 31, 2020 to December 31, 2021
Sale of common stock, net of transaction costs
From March 31, 2021 to June 30, 2021
Sale of common stock, net of transaction costs
1.Common stock offered 26,000,000 shares.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 71,468,755 shares of common stock outstanding as of May 3, 2021.
From December 31, 2020 to March 31, 2021
Sale of common stock, net of transaction costs
from December 31, 2019 to December 31, 2020
Sale of common stock, net of transaction costs
From June 30, 2020 to September 30, 2020
Sale of common stock, net of transaction costs
1.Common stock offered 14,285,715 shares of common stock.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 52,140,699 shares of common stock outstanding as of August 25, 2020.
From December 31, 2019 to March 10, 2020
Sale of common stock, net of transaction costs
1.Common stock offered 5,037,038 shares of common stock
2.The number of shares common stock to be outstanding immediately after this offering is based on 47,103,661 shares of common stock outstanding as of March 9, 2020 and excludes
1.Common stock offered 8,461,540 shares of common stock
2.The number of shares common stock to be outstanding immediately after this offering is based on 38,642,121 shares of common stock outstanding as of February 26, 2020
from December 31, 2018 to December 31, 2019
Sale of common stock, net of transaction costs
from December 31, 2018 to March 29, 2019
Sale of common stock, net of transaction costs
from December 31, 2017 to December 31, 2018
Exercise of common stock options
Sale of common stock, net of transaction costs
Convertible debt instruments
from December 31, 2017 to June 8, 2018
Exercise of common stock options
Sale of common shares and issuance of warrants
Convertible debt instruments
from December 31, 2017 to March 31, 2018
Exercise of common stock options
from December 31, 2016 to December 31, 2017
Exercise of common stock options
Sale of common stock